ArticleAntibody therapeutics2026
Llama mRNA-LNP immunization enables rapid isolation of target specific nanobodies using cell-based panning.
Article in Antibody therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a clinical vaccine platform, lipid nanoparticle (LNP)-formulated mRNA has demonstrated potent and broad antibody responses, prompting speculation about its potential for antibody discovery. Membrane proteins remain among the most challenging targets for antibody development, highlighting the urgent need for technologies that preserve their native conformation during immunization and screening. Nanobodies (V Methods: Here, we report the first demonstration of target specific V Results: This approach yielded multiple high-affinity spike-specific V Conclusions: These findings demonstrate the feasibility of mRNA-LNP immunization as a rapid and efficient method for isolating target specific, functionally promising V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.